
  
    
      
        Michael_NNP Makover_NNP 's_POS Viewpoint_NN :_: We_PRP Should_MD Use_NNP High-_NNP Sensitivity_NNP Carotid_NNP Ultrasound_NNP to_TO
        Detect_NNP Very_RB Early_RB Atherosclerosis_NNP and_CC Treat_NNP Aggressively_NNP
        Atherosclerotic_NNP vascular_NN disease_NN is_VBZ the_DT greatest_JJS cause_NN of_IN death_NN and_CC disability_NN in_IN
        developed_VBN countries_NNS ._. The_DT best_JJS way_NN to_TO prevent_VB these_DT outcomes_NNS is_VBZ to_TO detect_VB disease_NN at_IN the_DT
        earliest_JJS possible_JJ stage_NN and_CC to_TO attack_VB it_PRP with_IN pinpoint-targeted_JJ aggressive_JJ treatment_NN ._.
        B-_NNP mode_NN ultrasonography_NN of_IN the_DT carotid_NN artery_NN to_TO measure_VB the_DT intima-media_JJ thickness_NN (_( IMT_NNP )_)
        (_( Figure_NN 1_LS )_) is_VBZ the_DT most_RBS effective_JJ way_NN to_TO do_VB that_DT ._.
        It_PRP is_VBZ time_NN to_TO end_VB the_DT mindset_NN that_WDT thinks_VBZ of_IN atherosclerosis_NNS as_IN an_DT inevitable_JJ function_NN
        of_IN aging_VBG ._. It_PRP is_VBZ not_RB :_: it_PRP is_VBZ a_DT disease_NN ,_, whether_IN it_PRP causes_VBZ an_DT acute_JJ event_NN or_CC gradual_JJ decline_NN ._.
        As_IN with_IN any_DT disease_NN ,_, the_DT earlier_JJR and_CC more_RBR intensively_RB we_PRP attack_VBP it—with_NN medications_NNS and_CC
        lifestyle_NN changes—the_NN more_RBR successful_JJ we_PRP will_MD be_VB in_IN containing_VBG and_CC reversing_VBG it_PRP ._.
        Ultrasonography_NNP of_IN the_DT carotid_NN to_TO detect_VB plaque_NN and_CC increased_VBN intimal_NN wall_NN thickness_NN is_VBZ the_DT
        best_JJS ,_, safest_JJS ,_, and_CC easiest_JJS early_JJ detector_NN we_PRP have_VBP ._.
        Patients_NNS at_IN risk_NN for_IN atherosclerotic_JJ cardiovascular_JJ disease_NN are_VBP identifiable_JJ only_RB up_IN to_TO
        a_DT point_NN using_VBG traditional_JJ methods_NNS ,_, including_VBG the_DT Framingham_NNP risk_NN score_NN [_NN 1_CD ]_NN ,_, the_DT European_NNP
        SCORE_NNP (_( Systemic_NNP Coronary_NNP Risk_NNP Evaluation_NNP )_) [_NN 2_CD ]_NN ,_, and_CC the_DT C-_NNP reactive_JJ protein_NN level_NN [_NN 3_CD ]_NN ._. These_DT
        are_VBP particularly_RB effective_JJ for_IN people_NNS in_IN the_DT highest_JJS risk_NN groups_NNS ,_, but_CC they_PRP have_VBP serious_JJ
        flaws_NNS ._. They_PRP do_VBP not_RB take_VB family_NN history_NN of_IN premature_JJ coronary_JJ artery_NN disease_NN into_IN account_NN ;_:
        they_PRP do_VBP not_RB benefit_VB from_IN new_JJ assays_NNS that_WDT can_MD differentiate_VB lipoproteins_NNS by_IN particle_NN size_NN
        and_CC number_NN ,_, both_DT of_IN which_WDT are_VBP important_JJ factors_NNS in_IN atherogenicity_NN ;_: and_CC they_PRP do_VBP not_RB include_VB
        the_DT quality_NN of_IN the_DT patient_NN 's_POS diet_NN ,_, abdominal_NN fat_JJ content_NN ,_, racial_JJ and_CC ethnic_JJ genetic_JJ
        differences_NNS ,_, confounding_VBG medical_JJ conditions_NNS ,_, certain_JJ gender_NN differences_NNS ,_, and_CC other_JJ factors_NNS ._.
        Thus_RB ,_, many_JJ patients_NNS deemed_VBD “ low_JJ risk_NN” for_IN acute_JJ events_NNS within_IN a_DT period_NN of_IN time_NN might_MD still_RB
        develop_VB disease_NN ._.
        All_DT of_IN the_DT current_JJ risk_NN models_NNS were_VBD developed_VBN within_IN the_DT obsolete_JJ gestalt_NN of_IN life_NN spans_NNS
        of_IN perhaps_RB 60_CD to_TO 70_CD years_NNS ,_, whereas_IN people_NNS are_VBP now_RB increasingly_RB living_VBG productively_RB into_IN
        their_PRP$ 80_CD s_VBZ and_CC 90_CD s_VBZ ._. Risk_NN tables_NNS are_VBP based_VBN only_RB on_IN cardiac_JJ events_NNS over_IN a_DT relatively_RB short_JJ
        time_NN period_NN of_IN ten_CD years_NNS ._. Progress_NNP in_IN medical_JJ science_NN is_VBZ now_RB on_IN the_DT steepest_JJS slope_NN of_IN
        exponential_NN growth_NN ._. It_PRP is_VBZ reasonable_JJ to_TO expect_VB that_IN those_DT who_WP maintain_VBP healthy_JJ circulation_NN
        will_MD experience_VB good_JJ quality_NN life_NN beyond_IN the_DT 100_CD -_: year_NN mark_NN in_IN the_DT surprisingly_RB near_IN future_JJ ,_,
        and_CC perhaps_RB to_TO 120_CD years_NNS not_RB long_VBP after_IN ._. Furthermore_RB ,_, risk_NN escalates_NNS with_IN age_NN ._. Thus_RB ,_, an_DT
        initial_JJ low_JJ risk_NN profile_NN becomes_VBZ far_RB more_RBR significant_JJ when_WRB considered_VBN in_IN the_DT context_NN of_IN
        long_JJ lives_NNS ._. Equally_RB important_JJ ,_, gradual_JJ impairment_NN of_IN blood_NN flow_NN that_IN nourishes_NNS tissues_NNS can_MD
        lead_VB to_TO peripheral_JJ vascular_NN disease_NN ,_, increased_VBN susceptibility_NN to_TO infection_NN ,_, cognitive_JJ
        decline_NN ,_, frailty_NN ,_, and_CC other_JJ changes_NNS that_WDT impair_VB life_NN quality_NN and_CC longevity_NN ._.
        While_IN risk_NN factors_NNS help_VBP individualize_NN treatment_NN ,_, they_PRP do_VBP not_RB address_VB the_DT most_RBS critical_JJ
        issue_NN :_: identifying_VBG atherosclerosis_NNS at_IN the_DT very_RB earliest_JJS stage_NN to_TO try_VB to_TO stop_VB and_CC reverse_VB
        the_DT process_NN 
        before_IN any_DT damage_NN has_VBZ occurred_VBN ._. Risk_NN factors_NNS identify_VBP those_DT who_WP 
        might_MD develop_VB disease_NN ._. The_DT “ smoking_NN gun_NN” is_VBZ to_TO identify_VB disease_NN when_WRB it_PRP
        actually_RB first_JJ develops_VBZ ._. Atherosclerosis_NNP begins_VBZ as_IN a_DT lipid_NN and_CC inflammatory_JJ cell_NN deposition_NN
        in_IN the_DT intimal_NN subendothelial_NN space_NN ,_, which_WDT expands_VBZ outward_RB ,_, with_IN only_RB a_DT slight_JJ inward_RB
        intrusion_NN on_IN the_DT lumen_NN ._. This_DT does_VBZ not_RB affect_VB blood_NN flow_NN unless_IN the_DT lumen-side_JJ plaque_NN cap_NN
        ruptures_NNS ,_, and_CC a_DT clot_NN forms_NNS and_CC expands_VBZ into_IN the_DT blood_NN stream_NN ._. Most_JJS clots_NNS are_VBP limited_VBN by_IN
        thrombolytic_JJ mechanisms_NNS ,_, but_CC significant_JJ blockage_NN usually_RB results_VBZ as_IN the_DT clot_NN is_VBZ scarred_VBN
        over_IN ._. Some_DT clots_NNS expand_VBP all_PDT the_DT way_NN across_IN to_TO the_DT other_JJ side_NN of_IN the_DT artery_NN ,_, completely_RB
        occluding_VBG it_PRP ,_, causing_VBG a_DT heart_NN attack_NN or_CC stroke_NN [_NN 4_CD ]_NN ._.
        Thus_RB ,_, if_IN we_PRP could_MD discover_VB plaque_NN at_IN the_DT very_RB earliest_JJS stage_NN ,_, we_PRP could_MD aggressively_RB
        attack_VB it_PRP with_IN our_PRP$ full_JJ armamentarium_NN of_IN lifestyle_NN modification_NN ,_, addressing_VBG all_PDT the_DT factors_NNS
        noted_VBD above_IN ,_, and_CC medications—statins_NNS ,_, ACE_NNP inhibitors_NNS ,_, aspirin_NN ,_, niacin_NN ,_, ezetimibe_NN ,_, and_CC
        others—to_NN stabilize_VB and_CC then_RB reverse_VB the_DT process_NN before_IN a_DT rupture_NN occurs_VBZ ._. The_DT REVERSAL_NNP
        trial_NN ,_, among_IN many_JJ others_NNS ,_, has_VBZ shown_VBN that_IN atherosclerosis_NNS is_VBZ reversible_JJ with_IN aggressive_JJ
        treatment_NN [_NN 5_CD ]_NN ._. Carotid_NNP ultrasound_NN is_VBZ an_DT easy_JJ ,_, safe_JJ ,_, noninvasive_JJ method_NN for_IN detecting_VBG early_JJ ,_,
        focal_JJ plaques_NNS and_CC early_JJ thickening_VBG of_IN the_DT inner_JJ lining_NN of_IN the_DT artery_NN [_NN 6_CD ]_NN ._. There_EX is_VBZ ample_JJ
        evidence_NN that_IN this_DT is_VBZ an_DT effective_JJ and_CC reproducible_JJ detector_NN ,_, and_CC a_DT predictor_NN of_IN
        progression_NN and_CC symptomatic_JJ disease_NN [_NN 7_CD ]_NN ._. In_IN contrast_NN ,_, angiography_NN is_VBZ invasive_JJ and_CC is_VBZ
        insensitive_JJ to_TO early_JJ changes_NNS in_IN the_DT artery_NN wall_NN thickness_NN ._. Magnetic_JJ resonance_NN imaging_NN is_VBZ
        expensive_JJ ,_, cumbersome_JJ ,_, and_CC still_RB experimental_JJ ._. Calcium_NNP scoring_VBG by_IN computed_JJ tomography_NN is_VBZ
        less_RBR sensitive_JJ and_CC less_RBR reproducible_JJ and_CC suggests_VBZ plaque_NN presence_NN only_RB indirectly_RB [_NN 8_CD ]_NN ._.
        Angiography_NNP and_CC calcium_NN scoring_VBG entail_VB considerable_JJ X_NNP ray_NN exposure_NN ._.
        Using_VBG high-sensitivity_JJ carotid_NN ultrasound_NN as_IN a_DT primary_JJ screening_NN tool_NN would_MD add_VB modest_JJ
        cost_NN ,_, but_CC that_DT would_MD be_VB more_RBR than_IN offset_VBN by_IN sharply_RB reducing_VBG the_DT enormous_JJ worldwide_NN toll_NN of_IN
        atherosclerosis_NNS ._. Screening_NNP tests_NNS should_MD be_VB easy_JJ ,_, affordable_JJ ,_, widely_RB available_JJ ,_, and_CC
        predictive_JJ ._. Carotid_NNP ultrasound_NN meets_VBZ all_PDT these_DT criteria_NNS and_CC should_MD be_VB used_VBN to_TO screen_VB
        everyone_NN early_RB on_IN who_WP is_VBZ at_IN any_DT increased_VBN risk_NN by_IN measure_NN of_IN the_DT expanded_VBN risk_NN factors_NNS
        noted_VBD above_IN ._.
      
      
        Makover_NNP 's_POS Response_NNP to_TO Ebrahim_NNP 's_POS Viewpoint_NN
        While_IN the_DT “ population_NN” approach_NN is_VBZ obviously_RB very_RB important_JJ ,_, there_EX is_VBZ no_DT reason_NN not_RB to_TO
        use_VB the_DT “ high_JJ risk_NN” approach_NN as_RB well_RB ._. “ High_JJ risk_NN” is_VBZ the_DT wrong_JJ term—_NN
        all_DT arteries_NNS matter_VBP over_IN a_DT 120_CD -_: year_NN life_NN span_NN ._. We_PRP must_MD attack_VB
        atherosclerosis_NNS at_IN the_DT very_JJ onset_NN ,_, not_RB wait_VB until_IN it_PRP is_VBZ “ high_JJ risk_NN ._.” All_DT previous_JJ
        approaches_NNS were_VBD designed_VBN to_TO detect_VB those_DT at_IN allegedly_RB higher_JJR risk_NN by_IN various_JJ criteria_NNS ._. This_DT
        misses_VBZ the_DT point_NN ._. Once_RB plaque_NN exists_VBZ ,_, risk_NN exists_VBZ ,_, especially_RB when_WRB viewed_VBN over_IN a_DT full_JJ
        lifetime_NN ,_, not_RB the_DT current_JJ ten-year_JJ standard_NN ._. And_CC although_IN the_DT aggressive_JJ approach_NN I_PRP
        outlined_VBD in_IN my_PRP$ viewpoint_NN would_MD obviously_RB have_VB a_DT cost_NN ,_, the_DT savings_NNS (_( a_DT reduction_NN in_IN the_DT
        financial_JJ toll_NN of_IN cardiovascular_JJ disease_NN )_) would_MD be_VB greater_JJR than_IN the_DT cost_NN ._.
        Ultrasonography_NNP of_IN the_DT carotid_NN artery_NN intimal_NN wall_NN is_VBZ effective_JJ and_CC highly_RB predictive_JJ
        according_VBG to_TO the_DT great_JJ preponderance_NN of_IN studies_NNS [_NN 8_CD ]_NN ._. Ebrahim_NNP cites_VBZ two_CD studies_NNS to_TO support_VB
        his_PRP$ argument_NN that_IN measuring_VBG carotid_NN IMT_NNP offers_VBZ no_DT additional_JJ predictive_JJ power_NN over_IN
        conventional_JJ screening_NN tools_NNS [_NN 18_CD ,_, 19_CD ]_NN ,_, but_CC the_DT first_JJ of_IN these_DT has_VBZ serious_JJ flaws_NNS (_( such_JJ as_IN a_DT
        significant_JJ dropout_NN rate_NN that_IN the_DT authors_NNS assumed_VBD was_VBD random_JJ ,_, a_DT short_JJ follow-up_JJ period_NN ,_, and_CC
        the_DT inclusion_NN only_RB of_IN people_NNS of_IN an_DT advanced_VBN age_NN )_) [_NN 18_CD ]_NN ,_, and_CC the_DT other_JJ concluded_VBD that_DT carotid_NN
        IMT_NNP measurement_NN “ substantially_RB improved_VBD prediction_NN of_IN future_JJ coronary_JJ heart_NN disease_NN”
        [_NN 19_CD ]_NN ._.
        Millions_NNS of_IN people_NNS are_VBP at_IN risk_NN now_RB and_CC cannot_NN wait_NN for_IN endless_JJ studies_NNS to_TO prove_VB over_RB and_CC
        over_IN what_WP we_PRP already_RB know_VBP ._. It_PRP is_VBZ not_RB “ naïve_NN” for_IN well_JJ people_NNS to_TO want_VB to_TO remain_VB well_RB and_CC to_TO
        maintain_VB their_PRP$ arteries_NNS to_TO enable_VB healthy_JJ older_JJR lives_NNS ._. Nor_CC should_MD we_PRP disparage_VB as_IN “ worried_VBD”
        the_DT very_RB human_JJ desire_NN to_TO remain_VB that_DT way_NN ._. Population-wide_NNP planning_NN is_VBZ important_JJ ,_, but_CC
        doctors_NNS take_VBP care_NN of_IN each_DT patient_NN as_IN an_DT individual_NN ._. Carotid_NNP ultrasonography_NN is_VBZ by_IN far_RB the_DT
        best_JJS way_NN to_TO design_VB treatment_NN for_IN every_DT patient_NN exactly_RB as_IN needed_VBN ._. I_PRP believe_VBP that_IN there_EX is_VBZ
        already_RB sufficient_JJ evidence_NN and_CC sensible_JJ rationale_NN to_TO meld_VB already_RB well-proven_JJ technologies_NNS
        and_CC approaches_NNS into_IN a_DT comprehensive_JJ ,_, aggressive_JJ attack_NN on_IN atherosclerosis_NNS ._.
      
    
  
